Mortality from HIV‐associated meningitis in sub‐Saharan Africa: a systematic review and meta‐analysis
Open Access
- 19 January 2020
- journal article
- review article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 23 (1) , e25416
Abstract
Introduction: HIV‐associated cryptococcal, TB and pneumococcal meningitis are the leading causes of adult meningitis in sub‐Saharan Africa (SSA). We performed a systematic review and meta‐analysis with the primary aim of estimating mortality from major causes of adult meningitis in routine care settings, and to contrast this with outcomes from clinical trial settings.Methods: We searched PubMed, EMBASE and the Cochrane Library for published clinical trials (defined as randomized‐controlled trials (RCTs) or investigator‐managed prospective cohorts) and observational studies that evaluated outcomes of adult meningitis in SSA from 1 January 1990 through 15 September 2019. We performed random effects modelling to estimate pooled mortality, both in clinical trial and routine care settings. Outcomes were stratified as short‐term (in‐hospital or two weeks), medium‐term (up to 10 weeks) and long‐term (up to six months).Results and discussion: Seventy‐nine studies met inclusion criteria. In routine care settings, pooled short‐term mortality from cryptococcal meningitis was 44% (95% confidence interval (95% CI):39% to 49%, 40 studies), which did not differ between amphotericin (either alone or with fluconazole) and fluconazole‐based induction regimens, and was twofold higher than pooled mortality in clinical trials using amphotericin based treatment (21% (95% CI:17% to 25%), 17 studies). Pooled short‐term mortality of TB meningitis was 46% (95% CI: 33% to 59%, 11 studies, all routine care). For pneumococcal meningitis, pooled short‐term mortality was 54% in routine care settings (95% CI:44% to 64%, nine studies), with similar mortality reported in two included randomized‐controlled trials. Few studies evaluated long‐term outcomes.Conclusions: Mortality rates from HIV‐associated meningitis in SSA are very high under routine care conditions. Better strategies are needed to reduce mortality from HIV‐associated meningitis in the region.Keywords
Funding Information
- National Institute for Health Research (RP‐2017‐08‐ST2‐012)
- National Institute of Allergy and Infectious Diseases (F32AI140511)
This publication has 142 references indexed in Scilit:
- Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitisAIDS, 2012
- The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective studyAIDS Research and Therapy, 2012
- Cerebrospinal T-Cell Responses Aid in the Diagnosis of Tuberculous Meningitis in a Human Immunodeficiency Virus– and Tuberculosis-Endemic PopulationAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South AfricaJournal of Infection, 2010
- Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected casesBMC Infectious Diseases, 2010
- Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in MalawiClinical Infectious Diseases, 2010
- Sequelae due to bacterial meningitis among African children: a systematic literature reviewBMC Medicine, 2009
- Clinical presentation and aetiologies of acute or complicated headache among HIV‐seropositive patients in a Ugandan clinicJournal of the International AIDS Society, 2009
- Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2008
- Low CD4 count plus coma predicts cryptococcal meningitis in TanzaniaBMC Infectious Diseases, 2007